Blu-5937
- Generic Name
- Blu-5937
GSK to Present Groundbreaking Respiratory Medicine Data at ATS 2025 International Congress
• GSK will showcase 43 abstracts at the ATS 2025 International Congress, highlighting advancements in treatments for asthma and COPD with mepolizumab and depemokimab.
• New MATINEE trial analyses demonstrate mepolizumab's effectiveness in reducing COPD exacerbations and hospitalizations across various patient subgroups, including those with cardiovascular comorbidities.
• Twice-yearly dosing of depemokimab shows promising results in improving quality of life and reducing exacerbations in asthma patients with type 2 inflammation, potentially transforming treatment adherence.
Trevi Therapeutics' Haduvio Shows Promise for IPF-Related Cough Treatment, Receives Buy Rating
• Leerink Partners analyst maintains a Buy rating for Trevi Therapeutics with a $7.00 price target, citing Haduvio's potential in treating idiopathic pulmonary fibrosis (IPF) cough.
• The upcoming Phase 2a RIVER study for refractory chronic cough (RCC) is anticipated to deliver positive results, potentially strengthening the company's market position.
• IPF cough indication presents a clear commercial pathway with possible orphan drug designation, while expansion into RCC market faces competitive challenges requiring strong efficacy data.
Bayer Halts Development of Eliapixant Due to Safety Concerns
Bayer has discontinued the development of eliapixant, a P2X3 receptor antagonist, citing safety concerns despite promising clinical trial results. This decision follows the FDA's rejection of Merck & Co's similar drug, gefapixant, for the same reasons.
GSK Acquires Aiolos Bio for $1.4B, Expanding Asthma Treatment Portfolio with Novel TSLP Inhibitor
• GSK has announced a $1.4 billion acquisition of Aiolos Bio, including a $1 billion upfront payment, to secure AIO-001, a promising long-acting anti-TSLP antibody for severe asthma treatment.
• AIO-001 demonstrates potential advantages with twice-yearly dosing compared to current monthly treatments, and could benefit patients with both high and low T2 inflammation types of severe asthma.
• The acquisition strengthens GSK's respiratory medicine portfolio and follows their recent $2 billion Bellus Health purchase, showing strategic pipeline expansion ahead of key patent expirations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath